FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2324289718> ?p ?o ?g. }

• W2324289718 endingPage "djw005" @default.
• W2324289718 startingPage "djw005" @default.
• W2324289718 abstract "Although androgen deprivation therapy for advanced prostate cancer initially exerts excellent anticancer effects, most prostate cancer treated with androgen deprivation therapy eventually recurs as castration-resistant prostate cancer (CRPC). Although aberrant kinase activation has been proposed as a mechanism of castration resistance, comprehensive kinase profiles in CRPC remain unknown. Therefore, we aimed to elucidate the kinome in CRPC as well as the role of key molecules. We utilized a kinome array in androgen-dependent LNCaP and castration-resistant CxR cells. The effect of Y-box binding protein-1 (YB-1) on androgen receptor (AR) expression was examined by quantitative polymerase chain reaction and western blot analysis. The association between polymorphisms in the YB-1 gene determined by genotyping and YB-1 expression evaluated by immunohistochemistry in prostate cancer tissues, as well as outcome in metastatic prostate cancer, were investigated by the Cochran-Armitage test and the Cox proportional hazards model, respectively. All statistical tests were two-sided. One hundred fifty-six of 180 kinase phosphorylation sites, including ERK and RSK, were activated in CRPC cells, leading to increased phosphorylation of YB-1, which is a key molecule in the progression to CRPC. YB-1 signaling regulated AR V7 expression, and YB-1 inhibition augmented the anticancer effect of enzalutamide. Moreover, polymorphism (rs12030724) in the YB-1 gene affected YB-1 expression in 93 prostate cancer tissues (YB-1 positive rate; 14.3% in TT, 40.0% in AT, and 52.9% in AA, P = .04) and associated with probability of progression in 104 metastatic prostate cancer case patients (AT/TT vs AA, hazard ratio = 0.49, 95% confidence interval = 0.32 to 0.77, P = .001). YB-1 appears to be a promising target to inhibit the development of castration resistance, even at the AR variant–expressing stage. Polymorphism in the YB-1 gene may be a promising predictive biomarker in hormonal therapy." @default.
• W2324289718 created "2016-06-24" @default.
• W2324289718 creator A5000608465 @default.
• W2324289718 creator A5015753910 @default.
• W2324289718 creator A5019215076 @default.
• W2324289718 creator A5020076297 @default.
• W2324289718 creator A5032570626 @default.
• W2324289718 creator A5034672583 @default.
• W2324289718 creator A5034814953 @default.
• W2324289718 creator A5042141137 @default.
• W2324289718 creator A5044851719 @default.
• W2324289718 creator A5055007805 @default.
• W2324289718 creator A5059010005 @default.
• W2324289718 creator A5084151718 @default.
• W2324289718 date "2016-02-08" @default.
• W2324289718 modified "2023-10-16" @default.
• W2324289718 title "Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7" @default.
• W2324289718 cites W1496622454 @default.
• W2324289718 cites W1915769685 @default.
• W2324289718 cites W1977846760 @default.
• W2324289718 cites W1995039837 @default.
• W2324289718 cites W1995333503 @default.
• W2324289718 cites W1999343166 @default.
• W2324289718 cites W2005651997 @default.
• W2324289718 cites W2007951687 @default.
• W2324289718 cites W2010247911 @default.
• W2324289718 cites W2011826559 @default.
• W2324289718 cites W2015843104 @default.
• W2324289718 cites W2019607817 @default.
• W2324289718 cites W2020903165 @default.
• W2324289718 cites W2030176464 @default.
• W2324289718 cites W2032431432 @default.
• W2324289718 cites W2046815875 @default.
• W2324289718 cites W2048716594 @default.
• W2324289718 cites W2057867654 @default.
• W2324289718 cites W2060284451 @default.
• W2324289718 cites W2069824527 @default.
• W2324289718 cites W2072296682 @default.
• W2324289718 cites W2091898769 @default.
• W2324289718 cites W2095000952 @default.
• W2324289718 cites W2100495829 @default.
• W2324289718 cites W2102011014 @default.
• W2324289718 cites W2102051933 @default.
• W2324289718 cites W2110841612 @default.
• W2324289718 cites W2120012330 @default.
• W2324289718 cites W2122472408 @default.
• W2324289718 cites W2124864765 @default.
• W2324289718 cites W2139711232 @default.
• W2324289718 cites W2144169031 @default.
• W2324289718 cites W2145543322 @default.
• W2324289718 cites W2148643283 @default.
• W2324289718 cites W2150865892 @default.
• W2324289718 cites W2154893263 @default.
• W2324289718 cites W2156923287 @default.
• W2324289718 cites W2157750797 @default.
• W2324289718 cites W2157980218 @default.
• W2324289718 cites W2160683570 @default.
• W2324289718 cites W2164566492 @default.
• W2324289718 cites W2166918329 @default.
• W2324289718 cites W2169468059 @default.
• W2324289718 cites W2172161665 @default.
• W2324289718 cites W2267290488 @default.
• W2324289718 cites W4293409513 @default.
• W2324289718 doi "https://doi.org/10.1093/jnci/djw005" @default.
• W2324289718 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26857528" @default.
• W2324289718 hasPublicationYear "2016" @default.
• W2324289718 type Work @default.
• W2324289718 sameAs 2324289718 @default.
• W2324289718 citedByCount "52" @default.
• W2324289718 countsByYear W23242897182016 @default.
• W2324289718 countsByYear W23242897182017 @default.
• W2324289718 countsByYear W23242897182018 @default.
• W2324289718 countsByYear W23242897182019 @default.
• W2324289718 countsByYear W23242897182020 @default.
• W2324289718 countsByYear W23242897182021 @default.
• W2324289718 countsByYear W23242897182022 @default.
• W2324289718 countsByYear W23242897182023 @default.
• W2324289718 crossrefType "journal-article" @default.
• W2324289718 hasAuthorship W2324289718A5000608465 @default.
• W2324289718 hasAuthorship W2324289718A5015753910 @default.
• W2324289718 hasAuthorship W2324289718A5019215076 @default.
• W2324289718 hasAuthorship W2324289718A5020076297 @default.
• W2324289718 hasAuthorship W2324289718A5032570626 @default.
• W2324289718 hasAuthorship W2324289718A5034672583 @default.
• W2324289718 hasAuthorship W2324289718A5034814953 @default.
• W2324289718 hasAuthorship W2324289718A5042141137 @default.
• W2324289718 hasAuthorship W2324289718A5044851719 @default.
• W2324289718 hasAuthorship W2324289718A5055007805 @default.
• W2324289718 hasAuthorship W2324289718A5059010005 @default.
• W2324289718 hasAuthorship W2324289718A5084151718 @default.
• W2324289718 hasBestOaLocation W23242897181 @default.
• W2324289718 hasConcept C121608353 @default.
• W2324289718 hasConcept C126322002 @default.
• W2324289718 hasConcept C143998085 @default.
• W2324289718 hasConcept C184235292 @default.
• W2324289718 hasConcept C2776551883 @default.
• W2324289718 hasConcept C2777899217 @default.
• W2324289718 hasConcept C2777911890 @default.

• next